Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ELDN 
Eledon Pharmaceuticals Inc (ELDN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/13/2025: ELDN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $9.5
1 Year Target Price $9.5
| 5 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -77.41% | Avg. Invested days 22 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/13/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 164.08M USD | Price to earnings Ratio 4.22 | 1Y Target Price 9.5 |
Price to earnings Ratio 4.22 | 1Y Target Price 9.5 | ||
Volume (30-day avg) 6 | Beta 0.4 | 52 Weeks Range 2.31 - 5.54 | Updated Date 10/13/2025 |
52 Weeks Range 2.31 - 5.54 | Updated Date 10/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.65 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -41.4% | Return on Equity (TTM) 30.03% |
Valuation
Trailing PE 4.22 | Forward PE 5.39 | Enterprise Value 58506699 | Price to Sales(TTM) - |
Enterprise Value 58506699 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.84 | Shares Outstanding 59881775 | Shares Floating 39758337 |
Shares Outstanding 59881775 | Shares Floating 39758337 | ||
Percent Insiders 1.4 | Percent Institutions 72.79 |
Upturn AI SWOT
Eledon Pharmaceuticals Inc
Company Overview
History and Background
Eledon Pharmaceuticals Inc. (ELDN), formerly known as Novus Therapeutics, focuses on developing therapies for autoimmune and inflammatory diseases. Founded in 2011, the company has evolved through acquisitions and strategic shifts, primarily focusing on tegoprubart, a CD40-ligand antagonist.
Core Business Areas
- Pharmaceutical Development: Focuses on the research, development, and commercialization of novel therapeutics targeting CD40-ligand pathway for autoimmune and inflammatory diseases.
Leadership and Structure
The company is led by a management team with experience in the pharmaceutical industry. The organizational structure involves departments for research and development, clinical operations, regulatory affairs, and finance.
Top Products and Market Share
Key Offerings
- Tegoprubart: Tegoprubart is Eledon's lead product candidate, a CD40-ligand antagonist being developed for the treatment of islet cell transplantation (ICT) and amyotrophic lateral sclerosis (ALS). As a clinical-stage company, Eledon does not currently generate product revenue. Competitors in the immunosuppressant space include companies developing alternative therapies, such as Roche (ROG.SW) with anti-CD20 therapies and others targeting the immune system.
Market Dynamics
Industry Overview
The pharmaceutical industry, particularly in autoimmune and inflammatory diseases, is characterized by intense competition, high regulatory hurdles, and significant investment in research and development.
Positioning
Eledon is positioned as a company focused on targeting CD40-ligand pathway to treat diseases with high unmet medical needs. Competitive advantages depend on clinical trial success and potential for novel therapies.
Total Addressable Market (TAM)
The total addressable market for immunosuppressants and treatments for ALS is significant, estimated in the billions of dollars globally. Eledon's position depends on the success of tegoprubart in clinical trials and its ability to capture market share if approved.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach (CD40-ligand antagonism)
- Potential for breakthrough therapies in unmet medical needs
- Experienced management team
Weaknesses
- Clinical stage company with no current revenue
- High risk of clinical trial failure
- Dependence on single lead product candidate
Opportunities
- Successful clinical trial results and regulatory approval
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline through additional indications
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles and delays
- Failure to secure funding for development
Competitors and Market Share
Key Competitors
- ROG.SW
Competitive Landscape
Eledon's competitive advantage hinges on demonstrating superior efficacy and safety of tegoprubart compared to existing treatments and alternative therapies in development. The company currently has no approved drug and so no associated revenues.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by the progression of clinical trials and financing rounds.
Future Projections: Future growth projections are highly speculative and depend on the success of tegoprubart.
Recent Initiatives: Recent strategic initiatives likely include enrollment in clinical trials, presentations at medical conferences, and securing additional funding.
Summary
Eledon Pharmaceuticals is a clinical-stage company developing a novel CD40-ligand antagonist with potential in autoimmune and inflammatory diseases. Its success depends on positive clinical trial outcomes and securing funding. The company faces significant competition and regulatory hurdles, making its future uncertain. The ALS market is especially competitive.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Industry Reports
- Analyst Estimates
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Eledon Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Irvine, CA, United States | ||
IPO Launch date 2014-09-17 | CEO & Non Independent Director Dr. David-Alexandre C. Gros M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 31 | Website https://eledon.com |
Full time employees 31 | Website https://eledon.com | ||
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney transplantation and xenotransplantation. The company has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.